Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence

被引：28
作者：
Akazawa, Yuko [1 ]
Fukuda, Daisuke [2 ]
Fukuda, Yutaka [2 ]
机构：
[1] Nagasaki Univ Hosp, Dept Gastroenterol & Hepatol, 1-7-1 Sakamoto, Nagasaki 8528501, Japan
[2] Fukuda Yutaka Surg Clin, Nagasaki, Japan
来源：
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2016年 / 9卷 / 06期
关键词：
Vonoprazan; H; pylori; PPI; Takecab; potassium-competitive acid blocker; P-CAB; TAK-438; COMPETITIVE ACID BLOCKER; TRIPLE THERAPY; TAK-438; VONOPRAZAN; GASTRIC-CANCER; CLARITHROMYCIN; EFFICACY; TOLERABILITY; RESISTANCE; INFECTION; SAFETY;
D O I：
10.1177/1756283X16668093
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Stable suppression of gastric acid secretion is a crucial factor in Helicobacter pylori eradication. Vonoprazan is a potassium-competitive acid blocker recently approved for use in Japan. As vonoprazan has a long duration of action and causes rapid and strong inhibition of gastric acid secretion, it has gained clinical attention for treating erosive oesophagitis, peptic ulcers, and H. pylori infection. In this review, we discuss the recent knowledge regarding the safety and efficacy of vonoprazan, focusing on its use in H. pylori eradication. The latest literature and our clinical experience have shown that vonoprazan-based therapies have satisfactory eradication rates. Additionally, vonoprazan-based therapies are associated with similar rates of adverse events as standard triple therapies with conventional proton-pump inhibitors.
引用
收藏
页码：845 / 852
页数：8
相关论文
共 51 条
[1]  
Äbelö A, 2000, J PHARMACOL EXP THER, V295, P662
[2]   The Changing Profile of Helicobacter pylori Antibiotic Resistance in Singapore: A 15-Year Study [J].
Ang, Tiing Leong ;
Fock, Kwong Ming ;
Ang, Daphne ;
Kwek, Andrew Boon Eu ;
Teo, Eng Kiong ;
Dhamodaran, Subbiah .
HELICOBACTER, 2016, 21 (04) :261-265
[3]  
[Anonymous], ADV THER
[4]  
[Anonymous], IARC WORK GROUP REP
[5]   Discovery of a Novel Pyrrole Derivative 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Fumarate (TAK-438) as a Potassium-Competitive Acid Blocker (P-CAB) [J].
Arikawa, Yasuyoshi ;
Nishida, Haruyulci ;
Kurasawa, Osamu ;
Hasuoka, Atsushi ;
Hirase, Keizo ;
Inatomi, Nobuhiro ;
Hori, Yasunobu ;
Matsukawa, Jun ;
Imanishi, Akio ;
Kondo, Mitsuyo ;
Tarui, Naoki ;
Hamada, Teruki ;
Takagi, Terufumi ;
Takeuchi, Toshiyuki ;
Kajino, Masahiro .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (09) :4446-4456
[6]   Guidelines for the Management of Helicobacter pylori Infection in Japan: 2009 Revised Edition [J].
Asaka, Masahiro ;
Kato, Mototsugu ;
Takahashi, Shin-ichi ;
Fukuda, Yoshihiro ;
Sugiyama, Toshiro ;
Ota, Hiroyoshi ;
Uemura, Naomi ;
Murakami, Kazunari ;
Satoh, Kiichi ;
Sugano, Kentaro .
HELICOBACTER, 2010, 15 (01) :1-20
[7]   Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis [J].
Ashida, K. ;
Sakurai, Y. ;
Hori, T. ;
Kudou, K. ;
Nishimura, A. ;
Hiramatsu, N. ;
Umegaki, E. ;
Iwakiri, K. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (02) :240-251
[8]   Early Stellate Cell Activation and Veno-occlusive-disease (VOD)-like Hepatotoxicity in Dogs Treated with AR-H047108, an Imidazopyridine Proton Pump Inhibitor [J].
Berg, Anna-Lena ;
Bottcher, Gerhard ;
Andersson, Kjell ;
Carlsson, Enar ;
Lindstrom, Anna-Karin ;
Huby, Russell ;
Hakansson, Helen ;
Skanberg-Wilhelmsson, Inger ;
Hellmold, Heike .
TOXICOLOGIC PATHOLOGY, 2008, 36 (05) :727-737
[9]   Risk factors for failure of Helicobacter pylori therapy -: results of an individual data analysis of 2751 patients [J].
Broutet, N ;
Tchamgoué, S ;
Pereira, E ;
Lamouliatte, H ;
Salamon, R ;
Mégraud, F .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (01) :99-109
[10]   A Randomized, Comparative Trial of a Potassium-Competitive Acid blocker (AZD0865)and Esomeprazole for the Treatment of Patients With Nonerosive Reflux Disease [J].
Dent, John ;
Kahrilas, Peter J. ;
Hatlebakk, Jan ;
Vakil, Nimish ;
Denison, Hans ;
Franzen, Stefan ;
Lundborg, Per .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (01) :20-26
123456